Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24491906 | 0.96 | CHRM5 (0.46) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL15222417 | 0.94 | CHRM5 (0.50) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL24843742 | 0.91 | SCN1A (0.42) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL20756942 | 0.86 | ACHE (0.46) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL25489291 | 0.84 | CHRM5 (0.45) | CHRM5ADRA2CACHE | |
| SCHEMBL17108656 | 0.81 | ACHE (0.53) | CHRM5ADRA2CACHEOPRM1OPRD1 | |
| SCHEMBL25480261 | 0.80 | HRH3 (0.36) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL25489293 | 0.80 | CHRM5 (0.50) | CHRM5ADRA2CACHEGBA1SIGMAR1 | |
| SCHEMBL19807289 | 0.78 | CHRM5 (0.42) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL24925806 | 0.77 | ACHE (0.31) | CHRM5ADRA2CACHESCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CHRM5 4386/4885ADRA2C 3950/4885ACHE 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.